In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation
- PMID: 18221852
- DOI: 10.1016/j.diagmicrobio.2007.12.010
In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation
Erratum in
- Diagn Microbiol Infect Dis. 2008 Jul;61(3):366-8
Abstract
Twenty-three generic intravenous piperacillin/tazobactam products were compared for in vitro activity to the branded formulation (Zosyn, Wyeth, Philadelphia, PA) by disk diffusion and incremental broth microdilution assay methods. All but 1 lot demonstrated significantly decreased activity (-5 to -35%), necessitating further investigations regarding the chemical purity, potency, and therapeutic equivalence of these products worldwide. The average -16% activity across all generic lots was equivalent to underdosing piperacillin/tazobactam by 2.6 g daily for serious clinical infections (4.5 g Q6 h).
Comment in
-
Equal efficacy of a generic piperacillin/tazobactam formulation: results of a local screening protocol.Diagn Microbiol Infect Dis. 2011 Mar;69(3):286-7. doi: 10.1016/j.diagmicrobio.2010.10.006. Diagn Microbiol Infect Dis. 2011. PMID: 21353954 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical